Customizable Platform Technology
Enables High Affinity Monoclonal
Antibody Discovery
Isolated antibodies possess much greater drug binding and selectivity compared to previous efforts in the scientific literature
Pharmacokinetics of free drug
Substance of abuse distributes from blood to the brain, where it interacts with receptors to cause psychotropic and potentially dangerous effects.
Pharmacokinetics of drug-specific antibody
Our antibody therapy binds to the substance of abuse in the bloodstream, preventing it from getting into the brain and exerting its harmful and psychotropic effects.
Monoclonal antibodies sequester the substance of abuse in the bloodstream, preventing it from affecting the brain. The use of monoclonal antibodies allows for tight control of dosing as well as providing immediate protection after treatment. The monoclonal antibody is restricted to the blood stream, and thus not likely to have abuse potential of its own or to induce psychiatric side-effects common to other treatments for substance use disorders.
Our Pipeline
Product
Indication
Preclinical
CMC & Tox
Phase I
Phase II
Milestone
CSX-1004
mAb subcutaneous
Fentanyl Overdose Prevention
Phase 1a complete 2Q 2024
Phase 2a initiate 2Q 2024
Fentanyl Program
CSX-1004 (sBLA)
mAb subcutaneous
Opioid Use Disorder
Phase 2 initiate 2H 2025
Nicotine Program
CSX-3002
mAb subcutaneous
Smoking Cessation
Lead optimization
THC Program
CSX-5000
mAb infusion
Cannabis-Induced Psychosis
Lead optimization
CSX-1004 is a human monoclonal antibody directed against fentanyl and fentanyl analogs. It is being developed as a fixed-dose subcutaneous injection that is designed to provide protection from fentanyl overdose for at least 30 days. An ongoing Phase 1 clinical trial examining safety, tolerability, and pharmacokinetics of CSX-1004 is expected to complete in Q2 2024. CSX-1004 is also being evaluated for treatment of Opioid Use Disorder (OUD).
CSX-3002 is a monoclonal antibody being developed for the treatment of nicotine addiction. We have generated several high-affinity antibodies to nicotine, which are able to block nicotine’s effects in mice. Current studies are examining the efficacy of CSX-3002 in disrupting the behavioral effects of nicotine in rats.
Cessation is currently investigating several monoclonal antibody candidates against THC as well as synthetic cannabinoids. Antibodies generated in this program would offer treatment of acute overdose for which there is currently no approved medications.
Fentanyl Program
Nicotine Program
THC Program
Preclinical
CMC & Tox
Phase I
Phase II
CSX-1004 is a human monoclonal antibody directed against fentanyl and fentanyl analogs. It is being developed as a fixed-dose subcutaneous injection that is designed to provide protection from fentanyl overdose for at least 30 days. An ongoing Phase 1 clinical trial examining safety, tolerability, and pharmacokinetics of CSX-1004 is expected to complete in Q2 2024. CSX-1004 is also being evaluated for treatment of Opioid Use Disorder (OUD).
CSX-3002 is a monoclonal antibody being developed for the treatment of nicotine addiction. We have generated several high-affinity antibodies to nicotine, which are able to block nicotine’s effects in mice. Current studies are examining the efficacy of CSX-3002 in disrupting the behavioral effects of nicotine in rats.
Cessation is currently investigating several monoclonal antibody candidates against THC as well as synthetic cannabinoids. Antibodies generated in this program would offer treatment of acute overdose for which there is currently no approved medications.
Milestone
Phase 1a complete 2Q 2024
Phase 2a initiate 2Q 2024
Phase 2 initiate 2H 2025
Lead optimization
Lead optimization
Pharmacokinetics of free drug
Substance of abuse distributes from blood to the brain, where it interacts with receptors to cause psychotropic and potentially dangerous effects.
Plasma
CNS
Pharmacokinetics of drug-specific antibody
Our antibody therapy binds to the substance of abuse in the bloodstream, preventing it from getting into the brain and exerting its harmful and psychotropic effects.
blood-brain barrier